Correvio Pharma Corp. — Operating Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/efa05e7e-ef28-4338-aeaa-ea7148f3cfa6/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2019 | $-27.5M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-127179 |
| FY 2018 | $-26.3M | 2018-01-01 – 2018-12-31 | evidence 0001279569-19-000563 |
| FY 2017 | $-23.0M | 2017-01-01 – 2017-12-31 | evidence 0001279569-18-000852 |
| FY 2016 | $-14.6M | 2016-01-01 – 2016-12-31 | evidence 0001279569-17-000603 |
| FY 2015 | $-22.1M | 2015-01-01 – 2015-12-31 | evidence 0001279569-16-003027 |
| FY 2014 | $-16.6M | 2014-01-01 – 2014-12-31 | evidence 0001279569-15-000562 |
| FY 2013 | $-16.7M | 2013-01-01 – 2013-12-31 | evidence 0001279569-14-000490 |
| FY 2012 | $-26.0M | 2012-01-01 – 2012-12-31 | evidence 0001279569-13-000509 |
| FY 2011 | $-26.5M | 2011-01-01 – 2011-12-31 | evidence 0001171843-12-001415 |
| FY 2010 | $36.7M | 2010-01-01 – 2010-12-31 | evidence 0001171843-12-001415 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).